Spyre Therapeutics develops antibody drugs for inflammatory bowel disease and rheumatic conditions. SYRE reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in SYRE, 100% of them bullish and 0% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | UBS | Initiated | Buy | |
| Oct 1 | JP Morgan | Initiated | Buy | |
| Oct 1 | BTIG | Reiterated | Buy | |
| Aug 26 | Deutsche Bank | Target lowered | Buy | |
| Aug 26 | Wedbush | Target lowered | Buy |
Whale Options Flow
90DNo whale options trades in SYRE in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SYRE is in one of them and how their past SYRE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SYRE in an article yet. Here's the latest on the wider market.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company based in Waltham, Massachusetts, that develops antibody medicines. Its drug candidates are designed to act on the immune system and to last longer between doses, with the aim of treating inflammatory bowel disease, which includes ulcerative colitis and Crohn's disease. The company is also studying its anti-TL1A antibody for rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Its target patients are people living with these chronic immune conditions, and its products are still in development rather than on the market.
- Headquarters
- Waltham, MA
- Founded
- 2013
- Website
- aegleabio.com ↗